Repurposing Lithium for Parkinson's Disease

Parkinson's Disease Clinical Trial

Official title:

Repurposing Lithium as a Disease-modifying Therapy in Parkinson's Disease: A Phase I Trial

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT06099886
• Other study ID #: STUDY00007253
• Status: Enrolling by invitation
• Phase: Phase 1
• Start date: October 12, 2023
• Est. completion date: May 2025

Study information

• Verified date: December 2023
• Source: State University of New York at Buffalo
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will examine the effects of lithium aspartate 30-45mg/day on MRI biomarkers and blood-based therapeutic targets among 15 early-stage Parkinson's disease patients.

Description:

In observational studies, small daily doses of lithium have been associated with a 77% reduced risk of developing Parkinson's disease (PD). In addition, lithium therapy has been effective in preventing neuronal death and behavioral symptoms in several PD animal models. Recently, our group has shown 24-weeks of low-dose lithium aspartate therapy 45mg/day in PD to engage blood-based and the MRI disease progression biomarker, free water, to a greater extent than 15mg/day or 150mg/day of lithium carbonate. However, these blood-based and MRI biomarker findings stem from only four and two PD patients, respectively, who received lithium aspartate 45mg/day. In addition, two other PD patients receiving this dosage withdrew from the study due to side effects of sedation and dizziness. Subsequently, one of these patients who withdrew resumed lithium aspartate at 30mg/day and reported no side effects. Although these findings suggest that this dosage of lithium aspartate has positive effects on PD biomarkers, data from a larger number of PD patients will be required to justify conducting a larger, randomized controlled trial (RCT). The proposed study will enroll 15 additional PD patients over five months who will receive lithium aspartate 30-45mg/day for 24 weeks ensuring that the study will be completed within 12 months. The dosage will be slowly titrated in each patient up to the maximum tolerated dosage in this range. Blood-based biomarkers and MRIs will be assessed at baseline and 24 weeks. It is anticipated that a similar magnitude of biomarker engagement will be observed among these additional 15 patients as was seen in the handful from the pilot study. Such findings would provide strong preliminary evidence to support conducting a larger RCT including both clinical and biomarker outcomes. Positive results from such a RCT would support lithium aspartate as a disease-modifying therapy for PD.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 15
• Est. completion date: May 2025
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

Have PD for <4 years diagnosed by a movement disorder specialist. Have normal thyroid and renal function at the screening visit. Have no previous exposure to lithium therapy. Have no history of brain surgery. Have no hx of brain imaging findings suggesting another neurological condition besides PD. Have no use of tobacco or THC products for >1 year. Have stable PD medications for >30 days without current need for adjustments in the investigator's opinion. Have stable psychiatric and diuretic medications for >60 days with no anticipated need for changes for at least 24 weeks. Have no active medical or psychiatric condition that may interfere with study procedures in the investigator's opinion. Exclusion Criteria: Have PD for >4 years or does not have PD. Have abnormal normal thyroid and renal function at the screening visit. Have previous exposure to lithium therapy. Have history of brain surgery. Have hx of brain imaging findings suggesting another neurological condition besides PD. Have use of tobacco or THC products within the past year. Have PD medication adjustments within 30 days or needs PD medication adjustments in the investigator's opinion. Have psychiatric or diuretic medication adjustments within the last 60 days or is anticipated to need changes over next 24 weeks. Have active medical or psychiatric condition that may interfere with study procedures in the investigator's opinion.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Dietary Supplement:
• Lithium aspartate
Lithium aspartate 30-45mg/day

Locations

Country	Name	City	State
United States	University at Buffalo	Williamsville	New York

Sponsors (1)

Lead Sponsor	Collaborator
State University of New York at Buffalo

Country where clinical trial is conducted

United States, 

References & Publications (1)

Guttuso T Jr, Shepherd R, Frick L, Feltri ML, Frerichs V, Ramanathan M, Zivadinov R, Bergsland N. Lithium's effects on therapeutic targets and MRI biomarkers in Parkinson's disease: A pilot clinical trial. IBRO Neurosci Rep. 2023 May 7;14:429-434. doi: 10.1016/j.ibneur.2023.05.001. eCollection 2023 Jun. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adverse events	Number of patients with serious adverse events and number who withdraw from the study.	Through study completion, an average of 24 weeks.
Primary	MRI-derived free water (FW) levels	FW in the posterior substantia nigra (pSN), dorsomedial nucleus of the thalamus (DMN-T) and the nucleus basalts of Meynert (nbM).	Change from baseline (BL) to 24 weeks.
Primary	Peripheral blood mononuclear cell (PBMC) nuclear receptor-related 1 protein (Nurr1) mRNA expression.	PBMC Nurr1 mRNA expression using Taqman PCR.	Change from BL to 24 weeks.
Secondary	PBMC superoxide dismutase type-1 (SOD-1) mRNA expression	PBMC SOD-1 mRNA expression using Taqman PCR.	Change from BL to 24 weeks.
Secondary	PBMC pS9/total glycogen synthase kinase-3B (GSK-3B) ratio	Assessed using ELISA	Change from BL to 24 weeks.
Secondary	PBMC pThr308 and pS473/total protein kinase B (Akt) ratios	Assessed using ELISA	Change from BL to 24 weeks.
Secondary	Serum interleukin-6	Assessed using ELISA	Change from BL to 24 weeks.
Secondary	Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Motor Examination)	Assessed in the "on" state. Score range 0-132 with higher scores indicating worse outcomes.	Change from BL to 24 weeks.
Secondary	Montreal Cognitive Assessment (MoCA)	Score range 0-30 with higher scores indicating better outcomes.	Change from BL to 24 weeks.
Secondary	Parkinson's Anxiety Scale	Score range 0-48 with higher scores indicating worse outcomes.	Change from BL to 24 weeks.
Secondary	Geriatric Depression Scale-15	Score range 0-15 with higher scores indicating worse outcomes.	Change from BL to 24 weeks.
Secondary	Fatigue Severity Scale	Score range 9-63 with higher scores indicating worse outcomes.	Change from BL to 24 weeks.
Secondary	Insomnia Severity Index	Score range 0-28 with higher scores indicating worse outcomes.	Change from BL to 24 weeks.
Secondary	Parkinson's Disease Questionnaire-8	Score range 0-32 with higher scores indicating worse outcomes.	Change from BL to 24 weeks.
Secondary	Levodopa equilavent dose	Higher scores indicate higher dose of dopaminergic therapy.	Change from BL to 24 weeks.